Titre : Virus Junin

Virus Junin : Questions médicales fréquentes

Termes MeSH sélectionnés :

Policy Making
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Virus Junin : Questions médicales les plus fréquentes", "headline": "Virus Junin : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Virus Junin : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-21", "dateModified": "2025-04-15", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Virus Junin" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Arénavirus du Nouveau Monde", "url": "https://questionsmedicales.fr/mesh/D006477", "about": { "@type": "MedicalCondition", "name": "Arénavirus du Nouveau Monde", "code": { "@type": "MedicalCode", "code": "D006477", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B04.820.480.500.070.095" } } }, "about": { "@type": "MedicalCondition", "name": "Virus Junin", "alternateName": "Junin virus", "code": { "@type": "MedicalCode", "code": "D018051", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Cheng Huang", "url": "https://questionsmedicales.fr/author/Cheng%20Huang", "affiliation": { "@type": "Organization", "name": "Department of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America." } }, { "@type": "Person", "name": "Slobodan Paessler", "url": "https://questionsmedicales.fr/author/Slobodan%20Paessler", "affiliation": { "@type": "Organization", "name": "Department of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America." } }, { "@type": "Person", "name": "Duncan R Smith", "url": "https://questionsmedicales.fr/author/Duncan%20R%20Smith", "affiliation": { "@type": "Organization", "name": "Institute of Molecular Biosciences, Mahidol University, Salaya, 73170, Thailand. duncan_r_smith@hotmail.com." } }, { "@type": "Person", "name": "Vahid Rajabali Zadeh", "url": "https://questionsmedicales.fr/author/Vahid%20Rajabali%20Zadeh", "affiliation": { "@type": "Organization", "name": "Department of Emerging Infectious Diseases, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan." } }, { "@type": "Person", "name": "Shuzo Urata", "url": "https://questionsmedicales.fr/author/Shuzo%20Urata", "affiliation": { "@type": "Organization", "name": "Department of Emerging Infectious Diseases, National Research Center for the Control and Prevention of Infectious Diseases (CCPID), Nagasaki University, Nagasaki, Japan." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Applying behaviour change models to policy-making: development and validation of the Policymakers' Information Use Questionnaire (POLIQ).", "datePublished": "2023-01-23", "url": "https://questionsmedicales.fr/article/36691025", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12961-022-00942-y" } }, { "@type": "ScholarlyArticle", "name": "Research can be integrated into public health policy-making: global lessons for and from Spanish economic evaluations.", "datePublished": "2022-06-18", "url": "https://questionsmedicales.fr/article/35717247", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12961-022-00875-6" } }, { "@type": "ScholarlyArticle", "name": "Strengthening Governance and Institutional Capacity at the Nutrition-Food Supply Policy Nexus Comment on \"What Opportunities Exist for Making the Food Supply Nutrition Friendly? A Policy Space Analysis in Mexico\".", "datePublished": "2022-08-01", "url": "https://questionsmedicales.fr/article/35964160", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.34172/ijhpm.2022.7325" } }, { "@type": "ScholarlyArticle", "name": "Food system policy making and innovation at the local level: Exploring the response of Australian local governments to critical food systems issues.", "datePublished": "2022-06-19", "url": "https://questionsmedicales.fr/article/35718947", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/hpja.626" } }, { "@type": "ScholarlyArticle", "name": "Understanding accelerators to improve SDG-related outcomes for adolescents-An investigation into the nature and quantum of additive effects of protective factors to guide policy making.", "datePublished": "2023-01-06", "url": "https://questionsmedicales.fr/article/36607964", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0278020" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Virus", "item": "https://questionsmedicales.fr/mesh/D014780" }, { "@type": "ListItem", "position": 3, "name": "Virus à ARN", "item": "https://questionsmedicales.fr/mesh/D012328" }, { "@type": "ListItem", "position": 4, "name": "Virus à ARN de polarité négative", "item": "https://questionsmedicales.fr/mesh/D000086103" }, { "@type": "ListItem", "position": 5, "name": "Arenaviridae", "item": "https://questionsmedicales.fr/mesh/D001116" }, { "@type": "ListItem", "position": 6, "name": "Arenavirus", "item": "https://questionsmedicales.fr/mesh/D018050" }, { "@type": "ListItem", "position": 7, "name": "Arénavirus du Nouveau Monde", "item": "https://questionsmedicales.fr/mesh/D006477" }, { "@type": "ListItem", "position": 8, "name": "Virus Junin", "item": "https://questionsmedicales.fr/mesh/D018051" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Virus Junin - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Virus Junin", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-18", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Virus Junin", "description": "Comment diagnostique-t-on l'infection par le virus Junin ?\nQuels tests sont utilisés pour confirmer le virus Junin ?\nLes symptômes aident-ils au diagnostic du virus Junin ?\nPeut-on diagnostiquer le virus Junin par culture virale ?\nLe diagnostic précoce est-il important pour le virus Junin ?", "url": "https://questionsmedicales.fr/mesh/D018051?mesh_terms=Policy+Making&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Virus Junin", "description": "Quels sont les symptômes de l'infection par le virus Junin ?\nLa fièvre est-elle un symptôme courant du virus Junin ?\nLes symptômes du virus Junin peuvent-ils varier ?\nY a-t-il des symptômes neurologiques associés au virus Junin ?\nLes symptômes apparaissent-ils rapidement après l'infection ?", "url": "https://questionsmedicales.fr/mesh/D018051?mesh_terms=Policy+Making&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Virus Junin", "description": "Comment prévenir l'infection par le virus Junin ?\nLa vaccination contre le virus Junin est-elle disponible ?\nQuelles mesures d'hygiène sont recommandées ?\nLes rongeurs sont-ils un vecteur de transmission ?\nLes voyageurs doivent-ils se vacciner contre le virus Junin ?", "url": "https://questionsmedicales.fr/mesh/D018051?mesh_terms=Policy+Making&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Virus Junin", "description": "Quel est le traitement principal pour l'infection par le virus Junin ?\nDes antiviraux sont-ils efficaces contre le virus Junin ?\nLa transfusion sanguine est-elle utilisée dans le traitement ?\nLe traitement précoce améliore-t-il le pronostic ?\nY a-t-il des traitements expérimentaux pour le virus Junin ?", "url": "https://questionsmedicales.fr/mesh/D018051?mesh_terms=Policy+Making&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Virus Junin", "description": "Quelles sont les complications possibles de l'infection par le virus Junin ?\nLes complications surviennent-elles souvent ?\nLe virus Junin peut-il causer des séquelles à long terme ?\nLes complications sont-elles plus fréquentes chez certains groupes ?\nComment gérer les complications du virus Junin ?", "url": "https://questionsmedicales.fr/mesh/D018051?mesh_terms=Policy+Making&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Virus Junin", "description": "Quels sont les principaux facteurs de risque pour le virus Junin ?\nLes agriculteurs sont-ils à risque d'infection par le virus Junin ?\nLes personnes immunodéprimées sont-elles plus vulnérables ?\nLe sexe influence-t-il le risque d'infection par le virus Junin ?\nLes personnes vivant en milieu urbain sont-elles à risque ?", "url": "https://questionsmedicales.fr/mesh/D018051?mesh_terms=Policy+Making&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostique-t-on l'infection par le virus Junin ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests sérologiques et PCR pour détecter le virus." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour confirmer le virus Junin ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests ELISA et la PCR sont couramment utilisés pour confirmer l'infection." } }, { "@type": "Question", "name": "Les symptômes aident-ils au diagnostic du virus Junin ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes cliniques orientent le diagnostic, mais des tests sont nécessaires." } }, { "@type": "Question", "name": "Peut-on diagnostiquer le virus Junin par culture virale ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "La culture virale est possible mais moins courante en raison des risques de contagion." } }, { "@type": "Question", "name": "Le diagnostic précoce est-il important pour le virus Junin ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un diagnostic précoce permet une prise en charge rapide et améliore le pronostic." } }, { "@type": "Question", "name": "Quels sont les symptômes de l'infection par le virus Junin ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent fièvre, myalgies, fatigue, et parfois des hémorragies." } }, { "@type": "Question", "name": "La fièvre est-elle un symptôme courant du virus Junin ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la fièvre est l'un des symptômes les plus fréquents de l'infection." } }, { "@type": "Question", "name": "Les symptômes du virus Junin peuvent-ils varier ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'intensité et la nature des symptômes peuvent varier d'une personne à l'autre." } }, { "@type": "Question", "name": "Y a-t-il des symptômes neurologiques associés au virus Junin ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes neurologiques peuvent survenir, notamment des troubles de la conscience." } }, { "@type": "Question", "name": "Les symptômes apparaissent-ils rapidement après l'infection ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes apparaissent généralement 1 à 3 semaines après l'exposition au virus." } }, { "@type": "Question", "name": "Comment prévenir l'infection par le virus Junin ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention passe par l'évitement des contacts avec les rongeurs et la vaccination." } }, { "@type": "Question", "name": "La vaccination contre le virus Junin est-elle disponible ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une vaccination est disponible et recommandée pour les populations à risque." } }, { "@type": "Question", "name": "Quelles mesures d'hygiène sont recommandées ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Des mesures d'hygiène strictes, comme le nettoyage des lieux infestés, sont essentielles." } }, { "@type": "Question", "name": "Les rongeurs sont-ils un vecteur de transmission ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les rongeurs sont les principaux réservoirs et vecteurs du virus Junin." } }, { "@type": "Question", "name": "Les voyageurs doivent-ils se vacciner contre le virus Junin ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les voyageurs se rendant dans des zones endémiques doivent envisager la vaccination." } }, { "@type": "Question", "name": "Quel est le traitement principal pour l'infection par le virus Junin ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement est principalement symptomatique, avec des soins de soutien en cas de gravité." } }, { "@type": "Question", "name": "Des antiviraux sont-ils efficaces contre le virus Junin ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas d'antiviraux spécifiques approuvés pour le virus Junin." } }, { "@type": "Question", "name": "La transfusion sanguine est-elle utilisée dans le traitement ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des transfusions peuvent être nécessaires en cas de complications hémorragiques sévères." } }, { "@type": "Question", "name": "Le traitement précoce améliore-t-il le pronostic ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un traitement précoce et approprié peut améliorer le pronostic des patients." } }, { "@type": "Question", "name": "Y a-t-il des traitements expérimentaux pour le virus Junin ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des recherches sont en cours sur des traitements expérimentaux, mais rien n'est encore validé." } }, { "@type": "Question", "name": "Quelles sont les complications possibles de l'infection par le virus Junin ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications peuvent inclure des hémorragies, des troubles neurologiques et la mort." } }, { "@type": "Question", "name": "Les complications surviennent-elles souvent ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Les complications graves sont rares mais peuvent survenir chez certains patients." } }, { "@type": "Question", "name": "Le virus Junin peut-il causer des séquelles à long terme ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des séquelles neurologiques peuvent persister après la guérison de l'infection." } }, { "@type": "Question", "name": "Les complications sont-elles plus fréquentes chez certains groupes ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes immunodéprimées sont plus à risque de complications sévères." } }, { "@type": "Question", "name": "Comment gérer les complications du virus Junin ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "La gestion des complications nécessite des soins médicaux intensifs et un suivi approprié." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque pour le virus Junin ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'exposition aux rongeurs et le travail en zones endémiques." } }, { "@type": "Question", "name": "Les agriculteurs sont-ils à risque d'infection par le virus Junin ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les agriculteurs travaillant dans des zones infestées par des rongeurs sont à risque." } }, { "@type": "Question", "name": "Les personnes immunodéprimées sont-elles plus vulnérables ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles présentent un risque accru de développer des formes graves de la maladie." } }, { "@type": "Question", "name": "Le sexe influence-t-il le risque d'infection par le virus Junin ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Des études montrent que le risque peut varier selon le sexe, mais les raisons ne sont pas claires." } }, { "@type": "Question", "name": "Les personnes vivant en milieu urbain sont-elles à risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Le risque est généralement plus faible en milieu urbain, mais des cas sporadiques peuvent survenir." } } ] } ] }

Sources (10000 au total)

Applying behaviour change models to policy-making: development and validation of the Policymakers' Information Use Questionnaire (POLIQ).

The purpose of this study was to develop and validate the Policymakers' Information Use Questionnaire (POLIQ) to capture the intention of individuals in decision-making positions, such as health polic... The development and validation comprised three steps: item generation, qualitative face validation with cognitive debriefing and factorial construct validation. Confirmatory factor analysis was applie... Cognitive debriefing allowed for small adjustments in language for clarity, including simultaneous validation of the English and French questionnaires. Participants found that the questions were clear... Measuring decision-makers' behaviour in relation to research evidence use is challenging. We provide initial evidence on face validity and appropriate measurement properties of the POLIQ based on a co...

Strengthening Governance and Institutional Capacity at the Nutrition-Food Supply Policy Nexus Comment on "What Opportunities Exist for Making the Food Supply Nutrition Friendly? A Policy Space Analysis in Mexico".

Cervantes et al have provided an insightful addition to the policy literature by identifying the contextual, political, and policy factors that create constraints and opportunities for putting nutriti...

Food system policy making and innovation at the local level: Exploring the response of Australian local governments to critical food systems issues.

Urgent action is required by all levels of government to create a food system capable of nourishing a rapidly growing population while remaining within planetary boundaries. This study investigated po... An online survey was completed by LGs (n = 64) in New South Wales and Victoria, Australia. Questions focused on LGs' food system-related policies and programs, barriers to and enablers of engaging in ... Preventing food waste, organising food-related social/cultural events and providing potable water were the most commonly reported activities. Few LGs reported policies/activities on market gardening o... Australian LGs undertake a wide range of actions addressing diverse food system issues; however, internal and external barriers constrain their involvement in creating a healthy, sustainable and equit...

Understanding accelerators to improve SDG-related outcomes for adolescents-An investigation into the nature and quantum of additive effects of protective factors to guide policy making.

Recent evidence has shown support for the United Nations Development Programme (UNDP) accelerator concept, which highlights the need to identify interventions or programmatic areas that can affect mul...

Embedding rapid reviews in health policy and systems decision-making: Impacts and lessons learned from four low- and middle-income countries.

Demand for rapid evidence-based syntheses to inform health policy and systems decision-making has increased worldwide, including in low- and middle-income countries (LMICs). To promote use of rapid sy... While the selected platforms had experience in health policy and systems research and evidence syntheses, platforms were less confident conducting rapid evidence syntheses. A technical assistance cent... Platforms provided rapid syntheses across a range of AHPSR themes, and successfully engaged national- and state-level policy-makers. Examples of substantial policy impact were observed, including for ... The ERA initiative successfully established rapid response platforms in four LMICs. The short timeframe limited the number of rapid products produced, but there were examples of substantial impact and...

Uncovering the Effect of European Policy-Making Initiatives in Addressing Nutrition-Related Issues: A Systematic Literature Review and Bibliometric Analysis on Front-of-Pack Labels.

The last decades have been marked by the introduction of front-of-pack labels (FoPL) as an institutional corrective action against obesity and nutrition-related illnesses. However, FoPL-related policy...

From Local Action to Global Policy: A Comparative Policy Content Analysis of National Policies to Address Musculoskeletal Health to Inform Global Policy Development.

Global policy to guide action on musculoskeletal (MSK) health is in a nascent phase. Lagging behind other non-communicable diseases (NCDs) there is currently little global policy to assist governments... Multi-modal search strategy incorporating a systematic online search targeted at the 30 most populated nations; a call to networked experts; a specified question in a related eDelphi questionnaire; an... The search yielded 165 documents with 41 retained after removal of duplicates and exclusions. Only three documents were comprehensive national strategies addressing MSK health. The most common conditi... There are few examples of national strategic policy to address MSK health; however, many countries are moving towards this by documenting the burden of disease and developing policies for MSK services...

Inclusion of people with disabilities in Chilean health policy: a policy analysis.

Around 18% of the population in Chile has disabilities. Evidence shows that this population has greater healthcare needs, yet they face barriers to accessing healthcare due to health system failures. ... A policy content analysis was conducted of 12 health policy documents using the EquiFrame framework, adapted to assess disability inclusion. Documents were reviewed and rated on their quality of commi... Core human rights concepts of disability were mentioned at least once in nearly all health policy documents (92%). However, 50% had poor policy commitments for disability. Across policies, Prevention ... Improvements are needed in both the development and implementation of disability-inclusive health policies in Chile, to support the achievement of the right to healthcare for people with disabilities ...

Understanding successful policy innovation: The case of Portuguese drug policy.

In 2000, the Portuguese minority socialist government decriminalized the possession and consumption of drugs. This law made Portugal unique in having a formal system that directs the person using drug... After discussing the limitations of the existing literature, we present a new theoretical framework: the 'six-stars' framework. We argue that successful policy innovation in democracies will only occu... The proposed 'six-stars' framework of successful drug policy innovation shows the importance of electoral mandates, communication, inclusion, transparency, deliberation and evaluation when designing i...